Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2019 Feb 22

PMID 30790069

Citations 24

Authors

Karen Autio

Martin Oft

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Interleukin-10 (IL-10) is a cytokine with anti-inflammatory properties, which induces activation and proliferation of antigen-activated intratumoral CD8+ T cells. This review discusses the evolution of pegylated IL-10 (pegilodecakin) from preclinical investigation through first-in-human studies in oncology.

Recent Findings: Pegilodecakin was evaluated across multiple advanced solid tumors in a large phase 1/1b trial alone and in combination with chemotherapy or anti-PD-1 antibodies. Pegilodecakin monotherapy had immunologic and clinical activity in renal cell carcinoma (RCC) and uveal melanoma. In combination with anti-PD-1 inhibitors, pegilodecakin increased the responses in RCC and lung cancer with efficacy agnostic to PD-L1 status and tumor mutational burden. Pegilodecakin with FOLFOX had activity in pretreated pancreatic cancer, instructing the ongoing randomized phase III trial of the combination versus FOLFOX. The increased half-life of pegilodecakin enabled compelling preclinical data for IL-10 which has now been confirmed by clinical activity in a variety of cancers. The ability of pegilodecakin to both exert anti-tumor immunity and inhibit tumor-associated inflammation characterizes the uniqueness of this cytokine therapy.

Citing Articles

Future applications of host direct therapies for infectious disease treatment.

Thom R, DElia R Front Immunol. 2024; 15:1436557.

PMID: 39411713 PMC: 11473292. DOI: 10.3389/fimmu.2024.1436557.

BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses.

Lv Z, Wang T, Bi Y, Li D, Wu Q, Wang B Breast Cancer Res Treat. 2024; 209(2):405-418.

PMID: 39400783 DOI: 10.1007/s10549-024-07504-6.

Research progress on the PEGylation of therapeutic proteins and peptides (TPPs).

Li C, Li T, Tian X, An W, Wang Z, Han B Front Pharmacol. 2024; 15:1353626.

PMID: 38523641 PMC: 10960368. DOI: 10.3389/fphar.2024.1353626.

Targeting inflammation as cancer therapy.

Wang M, Chen S, He X, Yuan Y, Wei X J Hematol Oncol. 2024; 17(1):13.

PMID: 38520006 PMC: 10960486. DOI: 10.1186/s13045-024-01528-7.

Anti-CD20 treatment attenuates Th2 cell responses: implications for the role of lung follicular mature B cells in the asthmatic mice.

He J, Li J, Lin Q, Ni H, Huang S, Cheng H Inflamm Res. 2024; 73(3):433-446.

PMID: 38345634 DOI: 10.1007/s00011-023-01847-4.

References

Lauw F, Pajkrt D, Hack C, Kurimoto M, van Deventer S, van der Poll T . Proinflammatory effects of IL-10 during human endotoxemia. J Immunol. 2000; 165(5):2783-9. DOI: 10.4049/jimmunol.165.5.2783. View

Robert M, Jarlier M, Gourgou S, Desseigne F, Ychou M, Bouche O . Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4). Oncology. 2017; 93(6):367-376. DOI: 10.1159/000477850. View

Asadullah K, Docke W, Ebeling M, Friedrich M, Belbe G, Audring H . Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol. 1999; 135(2):187-92. DOI: 10.1001/archderm.135.2.187. View

van Deventer S, Elson C, Fedorak R . Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology. 1997; 113(2):383-9. DOI: 10.1053/gast.1997.v113.pm9247454. View

Chen W, Zlotnik A . IL-10: a novel cytotoxic T cell differentiation factor. J Immunol. 1991; 147(2):528-34. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Marlow G, van Gent D, Ferguson L . Why interleukin-10 supplementation does not work in Crohn's disease patients. World J Gastroenterol. 2013; 19(25):3931-41. PMC: 3703179. DOI: 10.3748/wjg.v19.i25.3931. View

Motzer R, Tannir N, Mcdermott D, Frontera O, Melichar B, Choueiri T . Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018; 378(14):1277-1290. PMC: 5972549. DOI: 10.1056/NEJMoa1712126. View

Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer S, Schreiber S . Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut. 2002; 50(2):191-5. PMC: 1773093. DOI: 10.1136/gut.50.2.191. View

10.

Finbloom D, Winestock K . IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol. 1995; 155(3):1079-90. View

11.

Mumm J, Emmerich J, Zhang X, Chan I, Wu L, Mauze S . IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell. 2011; 20(6):781-96. DOI: 10.1016/j.ccr.2011.11.003. View

12.

Groux H, Cottrez F, Rouleau M, Mauze S, Antonenko S, Hurst S . A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol. 1999; 162(3):1723-9. View

13.

Fiorentino D, Bond M, Mosmann T . Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989; 170(6):2081-95. PMC: 2189521. DOI: 10.1084/jem.170.6.2081. View

14.

Emmerich J, Mumm J, Chan I, LaFace D, Truong H, Mcclanahan T . IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res. 2012; 72(14):3570-81. DOI: 10.1158/0008-5472.CAN-12-0721. View

15.

Berman R, Suzuki T, Tahara H, Robbins P, Narula S, Lotze M . Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol. 1996; 157(1):231-8. View

16.

OGarra A, Barrat F, Castro A, Vicari A, Hawrylowicz C . Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev. 2008; 223:114-31. DOI: 10.1111/j.1600-065X.2008.00635.x. View

17.

Tilg H, Ulmer H, Kaser A, Weiss G . Role of IL-10 for induction of anemia during inflammation. J Immunol. 2002; 169(4):2204-9. DOI: 10.4049/jimmunol.169.4.2204. View

18.

Garon E, Rizvi N, Hui R, Leighl N, Balmanoukian A, Eder J . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018-28. DOI: 10.1056/NEJMoa1501824. View

19.

Zheng L, Ojcius D, Garaud F, Roth C, Maxwell E, Li Z . Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med. 1996; 184(2):579-84. PMC: 2192723. DOI: 10.1084/jem.184.2.579. View

20.

Pelzer U, Hilbig A, Sinn M, Stieler J, Bahra M, Dorken B . Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. Front Oncol. 2013; 3:155. PMC: 3682131. DOI: 10.3389/fonc.2013.00155. View